256
Participants
Start Date
July 7, 2016
Primary Completion Date
October 21, 2018
Study Completion Date
October 21, 2018
Ombitasvir/paritaprevir/ritonavir
Co-formulated tablet
Dasabuvir
Tablet
Ribavirin
Tablet
Patient support program
Supportive services provided to participants included reminder calls, emails, text messages, a Care Coach, and educational/informational materials.
Ha'Emek Medical Center /ID# 153695, Afula
Western Galilee Medical Center /ID# 153705, Nahariya
Hillel Yaffe Medical Center /ID# 153702, Hadera
Meir Medical Center /ID# 153698, Kfar Saba
The Edith Wolfson Medical Cent /ID# 153706, Holon
Assaf Harofeh Medical Center /ID# 153708, Be’er Ya‘aqov
Soroka Medical Center /ID# 169357, Beersheba
Soroka Medical Ctr /ID# 153697, Beersheba
Shaare Zedek Medical Center /ID# 153699, Jerusalem
Hadassah /ID# 153701, Jerusalem
Rambam Health Care Campus /ID# 153694, Haifa
Bnai Zion Medical Center /ID# 153700, Haifa
The Lady Davis Carmel MC /ID# 153692, Haifa
Rabin Medical Center /ID# 153696, Petakh Tikva
Rabin Medical Center /ID# 158648, Petakh Tikva
Sheba Medical Center /ID# 153707, Ramat Gan
Tel Aviv Sourasky Medical Ctr /ID# 153693, Tel Aviv
Maccabi Health Services /ID# 158647, GUSH DAN
Lead Sponsor
AbbVie
INDUSTRY